This is a routine KOL event filing with no new clinical data or financial results. The stock price impact is likely minimal. Monitor for the pivotal cohort 12-month data update and BLA filing expected in 2H 2026, which are the next major catalysts.
Price Chart
Executive Summary
enGene Therapeutics hosted a virtual KOL event on August 11, 2026, presenting market research on the NMIBC BCG-unresponsive opportunity for its lead candidate, detalimogene. The presentation included market sizing, pricing benchmarks (WAC up to $690K/year), and a commercial strategy targeting community urologists. The filing contains no new clinical data or financial results, only forward-looking market commentary.
Key Facts
- Hosted a virtual KOL event on August 11, 2026, to discuss NMIBC market research insights.
- Presented market research including >65 urologist interviews, >15 payer interviews, and >2,000 patient claims.
- Estimated annual WAC benchmark for NMIBC therapies has moved from $220K/year to $690K/year.
- Company has $285M in cash; pivotal cohort 12-month data and BLA filing expected in 2H 2026.
- No new clinical data or financial results were disclosed in the filing.
Financial Impact
No financial figures reported. Company disclosed $285M in cash on hand.
Risk Factors
- No guarantee detalimogene will successfully complete clinical development or achieve regulatory approval.
- Forward-looking market projections are based on management estimates and may not materialize.
- Competitive landscape includes approved therapies like Keytruda, Adstiladrin, Anktiva, and Inlexzo.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-344559 |
| Document: engn-ex99_1.htm | 0001193125-26-344559 |
| Document: 0001193125-26-344559-index-headers.html | 0001193125-26-344559 |
| Document: 0001193125-26-344559-index.html | 0001193125-26-344559 |
| Document: 0001193125-26-344559.txt | 0001193125-26-344559 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 7w ago | 8-K | $1.92 | awaiting T+60 | — | $1.55 (−19.27%) |
Aug 11, 2026 11w ago | 8-K | $1.70 | awaiting T+60 | — | $1.55 (−8.82%) |
Jul 16, 2026 14w ago | 8-K | $1.92 $1.73 | ▼ −9.90% | ▼ −13.61% | $1.55 (−19.27%) |
Jun 15, 2026 19w ago | 8-K | $1.77 $1.85 | ▼ −4.52% | ▼ −3.52% | $1.55 (+12.43%) |
Mar 3, 2026 34w ago | EFFECT | $9.66 $1.72 | ▼ −82.19% | ▼ −92.51% | $1.55 (−83.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers